Mutagenicity studies on tibezonium, a new oropharyngeal disinfectant

N,N-Diethyl-N-methyl-[2-[[4-(4-phenylthio) phenyl]-3H-1,5-benzodiazepin-2-yl]thio]-ethanaminium iodide) (tibezonium iodide; CAS-54663-47-7), a new oropharyngeal disinfectant, was tested, using the Ames procedure with and without metabolic activation, on five strains of Salmonella typhimurium and using the host mediated assay with Schizosaccharomyces pombe as microorganism test. In both tests the drug did not show any mutagenic activity when compared with mutagenic standards.